IN RE: YAZ®/YASMIN®/OCELLA® PRODUCT LIABILITY LITIGATION

THIS DOCUMENT APPLIES TO ALL CASES

SUPERIOR COURT OF NEW JERSEY LAW DIVISION: BERGEN COUNTY

CASE NO. 287

CIVIL ACTION

FILED

AUG 0 7 2015

CASE MANAGEMENT ORDER NO. 53

BRIAN R. MARTINOTTI, J.S.C.

ATE Settlement Implementation Modification

The negotiating parties having agreed to a modification of footnotes four and five of the Master Settlement Agreement (MSA) which is attached as Exhibit A to Case Management Order 49, the Court hereby acknowledges the modification which is made a part of the MSA by said further written agreement of the parties and which is attached hereto in three pages containing the relevant signatures.

Accordingly, the Court hereby directs Liaison and Lead Counsel for plaintiffs to distribute this modification to all counsel for dissemination to the plaintiffs in this litigation for their consideration.

SO OBBURED

Honorable Brian R. Martinotti, JSC

MODIFICATION TO ATE MASTER SETTLEMENT AGREEMENT

This Agreement, dated August 6, 2015, shall be a binding modification to the ATE Master Settlement Agreement, dated August 3, 2015 entered into by and between (i) Bayer HealthCare Pharmaceuticals Inc. ("BHCP"), and (ii) the plaintiffs' counsel listed in the signature pages hereto under the heading "Negotiating Plaintiffs' Counsel" ("NPC") (collectively referred to herein as the "Parties") (the "Modification"). Only those terms listed in this Modification shall be changed all other terms of the MSA shall remain in full force and effect.

1) The Parties hereby agree that footnote 4 of the MSA shall be modified and shall read as follows:

"Any percentage adjustment upward for an enhancement shall be an adjustment based on the Base Point Award to the individual Claimant and shall not be cumulative. Any percentage adjustment downward shall be computed as follows: (a) the first downward adjustment shall be based on the adjusted or gross Point Award after enhancements have been applied, and (b) any subsequent downward adjustment shall be based on the new or adjusted Point Award in order to avoid downward adjustments resulting in zero points and (c) the largest percentage downward adjustment shall be taken first and in descending sequence thereafter."

2) The Parties hereby agree that footnote 5 of the MSA shall be modified and shall read as follows:

"Risk Factor Reductions are to be applied sequentially, rather than added together and then applied. This means that if more than one applies, they are applied in sequence to reduce the new or adjusted Point Award. For example, apply -75% for illegal drug use, then apply -30% for BMI, rather than adding them together and reducing by 105%."

3) No other changes or modifications to the MSA are being made by this Modification.

IN WITNESS WHEREOF, NPC and BHCP have executed this Modification to the ATE Master Settlement Agreement effective as of the Execution Date.

Bayer HealthCare Pharmaceuticals Inc.

august 6, 2015

Bayer HealthCare Pharmaceuticals Inc.

MODIFICATION TO ATE MASTER SETTLEMENT AGREEMENT

This Agreement, dated August 6, 2015, shall be a binding modification to the ATE Master Settlement Agreement, dated August 3, 2015 entered into by and between (i) Bayer HealthCare Pharmaceuticals Inc. ("BHCP"), and (ii) the plaintiffs' counsel listed in the signature pages hereto under the heading "Negotiating Plaintiffs' Counsel" ("NPC") (collectively referred to herein as the "Parties") (the "Modification"). Only those terms listed in this Modification shall be changed all other terms of the MSA shall remain in full force and effect.

1) The Parties hereby agree that footnote 4 of the MSA shall be modified and shall read as follows:

"Any percentage adjustment upward for an enhancement shall be an adjustment based on the Base Point Award to the individual Claimant and shall not be cumulative. Any percentage adjustment downward shall be computed as follows: (a) the first downward adjustment shall be based on the adjusted or gross Point Award after enhancements have been applied, and (b) any subsequent downward adjustment shall be based on the new or adjusted Point Award in order to avoid downward adjustments resulting in zero points and (c) the largest percentage downward adjustment shall be taken first and in descending sequence thereafter."

2) The Parties hereby agree that footnote 5 of the MSA shall be modified and shall read as follows:

"Risk Factor Reductions are to be applied sequentially, rather than added together and then applied. This means that if more than one applies, they are applied in sequence to reduce the new or adjusted Point Award. For example, apply -75% for illegal drug use, then apply -30% for BMI, rather than adding them together and reducing by 105%."

3) No other changes or modifications to the MSA are being made by this Modification.

IN WITNESS WHEREOF, NPC and BHCP have executed this Modification to the ATE Master Settlement Agreement effective as of the Execution Date.

Bayer HealthCare Pharmaceuticals Inc.
, 2015
Bayer HealthCare Pharmaceuticals Inc.

Negotiating Plaintiffs' Counsel

Burg Simpson Eldredge Hersh & Jardine, P.C. 40 Inverness Drive East Englewood, CO 20110

Phone: (303) 792-5595

Fax: (303) 708-0527 yazatenotice@burgsimpson.com

Michael A. London

Michael A. London

2015

Douglas & London, P.C.

59 Maiden Lane, 6th Floor

New York, NY 10038

Phone: (212) 566-7500

Fax: (212) 566-7501

miondon@douglasandlondon.com

Richard D. Meadow

The Lanier Law Firm 126 East 56th Street New York, NY 10022 Phone: (212) 421-2800 Fax: (917) 546-0464 rdm@lanierlawfirm.com

Daniel S. Robinson

Robinson Calcagnie Robinson Shapiro & Davis, Inc. 19 Corporate Plaza Drive Newport Beach, CA 92660

Phone: (949) 720-1288 Fax: (949) 720-1292 drobinson@rorsd.com

Weinkowitz

Levin Fishbein Sedran & Berman

510 Walnut Street, Suite 500 Philadelphia, PA 19106

Phone; (215) 592-1500
Fax: (215) 592-4663
mweinkowitz@lfsblaw.com

Richard D. Meadow

The Lanier Law Firm 126 East 56th Street New York, NY 10022 Phone: (212) 421-2800 Fax: (917) 546-0464 rdm@lanierlawfirm.com

Daniel S. Robinson 8 2015 Robinson Calcagnie Robinson Shapiro & Davis, Inc. 19 Corporate Plaza Drive

Newport Beach, CA 92660 Phone: (949) 720-1288 Pax: (949) 720-1292

drobinson@rersd.com

Michael M. Weinkowitz 2015 Levin Pshbein Sedran & Berman 510 Walnut Street, Suite 500

Philadelphia, PA 19106

Phone: (215) 592-1500 Fax: (215) 592-4663

mweinkowitz@lfsblaw.com